First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac

On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium

doi:10.1016/j.tipsro.2022.04.005

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac

On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium

Netherlands Cancer Institute
Royal Marsden NHS Foundation Trust
University of Brescia
University of Toronto
University of Southern Denmark
University of Tübingen
Medical College of Wisconsin
Utrecht University

Research output: Contribution to journal › Article › peer-review

Abstract

The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.

Original language	English
Pages (from-to)	50-54
Number of pages	5
Journal	Technical Innovations and Patient Support in Radiation Oncology
Volume	22
DOIs	https://doi.org/10.1016/j.tipsro.2022.04.005
Publication status	Published - Jun 2022
Externally published	Yes

Keywords

(3–6): oligometastases
MOMENTUM
MR-guided radiotherapy
MR-Linac
SABR

Access to Document

10.1016/j.tipsro.2022.04.005

Cite this

@article{6e0b222df7264fc099b4238826a19389,

title = "First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac",

abstract = "The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.",

keywords = "(3–6): oligometastases, MOMENTUM, MR-guided radiotherapy, MR-Linac, SABR",

author = "\{On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium\} and Janssen, \{Tomas M.\} and Katharine Aitken and Filippo Alongi and Aisling Barry and Uffe Bernchou and Simon Boeke and Hall, \{William A.\} and Ali Hosni and Kroon, \{Petra S.\} and Marcel Nachbar and Hina Saeed and J{\"u}rgenliemk-Schulz, \{Ina M.\} and Tine Schytte and Verkooijen, \{Helena M.\} and Nowee, \{Marlies E.\}",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = jun,

doi = "10.1016/j.tipsro.2022.04.005",

language = "English",

volume = "22",

pages = "50--54",

journal = "Technical Innovations and Patient Support in Radiation Oncology",

issn = "2405-6324",

publisher = "Elsevier Ireland Ltd",

}

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. / On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium.
In: Technical Innovations and Patient Support in Radiation Oncology, Vol. 22, 06.2022, p. 50-54.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac

AU - On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium

AU - Janssen, Tomas M.

AU - Aitken, Katharine

AU - Alongi, Filippo

AU - Barry, Aisling

AU - Bernchou, Uffe

AU - Boeke, Simon

AU - Hall, William A.

AU - Hosni, Ali

AU - Kroon, Petra S.

AU - Nachbar, Marcel

AU - Saeed, Hina

AU - Jürgenliemk-Schulz, Ina M.

AU - Schytte, Tine

AU - Verkooijen, Helena M.

AU - Nowee, Marlies E.

PY - 2022/6

Y1 - 2022/6

N2 - The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.

AB - The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.

KW - (3–6): oligometastases

KW - MOMENTUM

KW - MR-guided radiotherapy

KW - MR-Linac

KW - SABR

UR - https://www.scopus.com/pages/publications/85129945098

U2 - 10.1016/j.tipsro.2022.04.005

DO - 10.1016/j.tipsro.2022.04.005

M3 - Article

AN - SCOPUS:85129945098

SN - 2405-6324

VL - 22

SP - 50

EP - 54

JO - Technical Innovations and Patient Support in Radiation Oncology

JF - Technical Innovations and Patient Support in Radiation Oncology

ER -

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this